Q3'25 Investor Survey: What are Investors Most Concerned About?

Investor enthusiasm for bringing psychedelic therapies to market stays strong, but regulatory and legislative barriers are identified as the dominant concern in Psychedelic Alpha's Q3'25 investor survey. Beyond regulation, investors increasingly focus on post-approval commercial realities, including rollout challenges, gaps in infrastructure and workforce, and uncertain reimbursement pathways. While concerns about trial outcomes and development timelines appear to have eased, political uncertainty is said to be rising in relevance even as many investors view changes in the U.S. administration positively. The survey organizes investor worries into multiple areas, including safety and ethics, stigma, political uncertainty, trial and timeline risk, return on investment, funding sources and uses, and execution risks like bankruptcy and company performance, plus concerns about interference from large pharmaceutical interests.